ADMA receives FDA approval for 10th plasma collection center; achieves plasma supply self-sufficiency

ADMA BIOLOGICS, INC.

FDA approval for Laurel, MD facility (10th ADMA BioCenters center) to introduce source plasma into interstate commerce.
Facility began operations and collection in H1 2023; now licensed for further manufacturing in the U.S.
Management says approval accomplishes goal of plasma self-sufficiency, supporting revenue growth and profitability outlook.
Center uses Haemonetics NexSys Persona® collection system; expects ~50 staff at full capacity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.